Document Type
Article
Publication Date
6-2025
Identifier
DOI: 10.1111/cts.70262; PMCID: PMC12117883
Abstract
Glucagon-like peptide-1 agonists (GLP-1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents. Emerging evidence suggesting neuropsychiatric effects presents an opportunity for pediatric psychopharmacology but requires careful consideration of potential adverse effects and risk of misuse. This perspective examines potential applications and cautions surrounding GLP-1As for pediatric mental health, particularly substance use, depression, and eating disorders, and advocates for research and clinical monitoring to ensure their safety and efficacy.
Journal Title
Clin Transl Sci
Volume
18
Issue
6
First Page
70262
Last Page
70262
MeSH Keywords
Humans; Child; Adolescent; Glucagon-Like Peptide 1; Diabetes Mellitus, Type 2; Psychopharmacology; Substance-Related Disorders; Glucagon-Like Peptide-1 Receptor Agonists; Pediatric Obesity; Feeding and Eating Disorders
PubMed ID
40434284
Keywords
Glucagon-Like Peptide 1; Diabetes Mellitus, Type 2; Psychopharmacology; Substance-Related Disorders; Glucagon-Like Peptide-1 Receptor Agonists; Pediatric Obesity; Feeding and Eating Disorders
Recommended Citation
Bartkoski M, Poweleit EA, Stancil SL. GLP-1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions. Clin Transl Sci. 2025;18(6):e70262. doi:10.1111/cts.70262
Comments
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Publisher's Link: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70262